55 related articles for article (PubMed ID: 8858979)
1. Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines.
Debernardis D; Stanzione S; Ottoboni C; Clerico L; Mancuso T; Parodi S; Russo P
J Pharmacol Exp Ther; 1996 Oct; 279(1):84-90. PubMed ID: 8858979
[TBL] [Abstract][Full Text] [Related]
2. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
3. Phorbol 12-myristate 13-acetate protects against tumor necrosis factor (TNF)-induced necrotic cell death by modulating the recruitment of TNF receptor 1-associated death domain and receptor-interacting protein into the TNF receptor 1 signaling complex: Implication for the regulatory role of protein kinase C.
Byun HS; Park KA; Won M; Yang KJ; Shin S; Piao L; Kwak JY; Lee ZW; Park J; Seok JH; Liu ZG; Hur GM
Mol Pharmacol; 2006 Sep; 70(3):1099-108. PubMed ID: 16798936
[TBL] [Abstract][Full Text] [Related]
4. [Anti-proliferative effects of tumor necrosis factor and gamma interferon on human ovarian cancer cell lines].
Li J; Liu YL; Sha JY
Zhonghua Fu Chan Ke Za Zhi; 1994 Nov; 29(11):670-2, 700. PubMed ID: 7712890
[TBL] [Abstract][Full Text] [Related]
5. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Niiya M; Niiya K; Kiguchi T; Shibakura M; Asaumi N; Shinagawa K; Ishimaru F; Kiura K; Ikeda K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2003 Nov; 52(5):391-8. PubMed ID: 12908082
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells.
Cimoli G; Valenti M; Venturini M; Conte P; Russo P
Anticancer Res; 1992; 12(5):1411-4. PubMed ID: 1444198
[TBL] [Abstract][Full Text] [Related]
7. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells.
Lee S; Yoon S; Kim DH
Gynecol Oncol; 2007 Feb; 104(2):338-44. PubMed ID: 17023032
[TBL] [Abstract][Full Text] [Related]
8. TNF-alpha-induced growth suppression of CD34+ myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-kappa B activation.
Hu X; Tang M; Fisher AB; Olashaw N; Zuckerman KS
J Immunol; 1999 Sep; 163(6):3106-15. PubMed ID: 10477576
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft.
Noviello E; Cimoli G; Cosimi A; Allievi E; Galletti P; Parodi S; Russo P
Cytokine; 1996 Apr; 8(4):330-3. PubMed ID: 9162224
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptors.
Kost ER; Mutch DG; Herzog TJ
Gynecol Oncol; 1999 Mar; 72(3):392-401. PubMed ID: 10053112
[TBL] [Abstract][Full Text] [Related]
11. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
12. Effect of recombinant human TNF on human ovarian cancer cell lines.
Vigani A; Miglietta L; Chiara S; Repetto L; Pichi E; Cimoli G; Morelli L; Poggi L; Billi G; Parodi S
Boll Soc Ital Biol Sper; 1990 Jun; 66(6):537-42. PubMed ID: 2257120
[TBL] [Abstract][Full Text] [Related]
13. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.
Kulbe H; Hagemann T; Szlosarek PW; Balkwill FR; Wilson JL
Cancer Res; 2005 Nov; 65(22):10355-62. PubMed ID: 16288025
[TBL] [Abstract][Full Text] [Related]
14. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
15. Comparison of TNFalpha and TNFbeta cytolytic mechanisms in human ovarian and cervical carcinoma cell lines.
Powell CB; Scott JH; Collins JL
Gynecol Oncol; 1998 Nov; 71(2):258-65. PubMed ID: 9826469
[TBL] [Abstract][Full Text] [Related]
16. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
Kim D; Lee IS; Jung JH; Lee CO; Choi SU
Anticancer Res; 1999; 19(5B):4085-90. PubMed ID: 10628358
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
18. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
19. Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells.
Yang WL; Roland IH; Godwin AK; Xu XX
Oncogene; 2005 Dec; 24(54):7991-8002. PubMed ID: 16044148
[TBL] [Abstract][Full Text] [Related]
20. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
